Navigation Links
Watson Names Mark Durand Chief Financial Officer
Date:11/16/2007

CORONA, Calif., Nov. 16 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced the appointment of Mark W. Durand, 48, as Senior Vice President and Chief Financial Officer.

Mr. Durand brings to Watson more than 20 years of executive pharmaceutical experience in finance, operations, business development and marketing. As Senior Vice President and Chief Financial Officer for Watson, Mr. Durand will be responsible for all of the Company's financial operations and will play a principal role in Watson's corporate development activities. He will report directly to Paul Bisaro, Watson's President and Chief Executive Officer.

"We are excited to bring someone with Mark's experience to join the executive management team," said Paul Bisaro. "His extensive experience in both the generic and branded pharmaceutical industries and familiarity with our business model will complement the strength we have within our finance and corporate development groups as we continue to position Watson for future growth."

Mr. Durand joins Watson following his position as Chief Financial Officer and Senior Vice President Finance and Business Development for Teva Pharmaceuticals N.A., where he was responsible for all financial functions and business development activities related to Teva's North America operations, including licensing activities. He also played an integral role in the integration of Ivax Pharmaceuticals after it was acquired by Teva. Prior to his tenure at Teva, Mr. Durand held a number of positions of growing responsibility in the areas of finance, business development and marketing at Bristol-Myers Squibb. His financial roles there included Vice President US Pharmaceutical Group and Vice President Finance and Business Development for Bristol's Worldwide Consumer Medicines and Specialty Pharmaceuticals Division.

Mr. Durand received a Bachelor of Science degree in Zoology from Duke University, a Master of Science degree in Biological Sciences from Dartmouth College and a Master of Business Administration from the University of Chicago.

Forward-Looking Statement

Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's Annual Report on Form 10-K for the year ended December 31, 2006.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO)


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
2. Watson Wyatt Identifies Major Benefit Trends During Open Enrollment Season
3. Texas Affiliates of Susan G. Komen for the Cure, Sen. Kirk Watson, Rep. Patrick Rose, Singer Kelly Willis, Breast Cancer Survivors and Activists Rally for Passage of Proposition 15
4. Watson Files FDA Application for Generic YAZ(R)
5. ResMed Names Kieran Gallahue as Chief Executive Officer, Effective January 1, 2008.
6. Mediware Names Thomas K. Mann Chief Executive Officer
7. Cleveland-based Health Care Tech Company Within3 Names New CEO
8. STERIS Corporation Board of Directors Names Walter M. Rosebrough Jr. President and Chief Executive Officer
9. Patient Safety Authority Board of Directors Names Infection Advisory Panel
10. Hooper Holmes Names Chris Behling President of Health & Wellness Division
11. MDMA Names New Director of Federal Affairs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in ... ways they remain in the eye of the beholder, according to experts who offered ... The American Journal of Managed Care. For the full issue, click here . ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... PawPaws ... a new product that was developed to enhance the health of felines. The formula ... , The two main herbs in the PawPaws Cat Kidney Support Supplement ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes ... important health care topics including advance care planning, healthcare costs and patient and ...
(Date:6/25/2016)... , ... June 25, 2016 , ... "With 30 hand-drawn ... specific project," said Christina Austin - CEO of Pixel Film Studios. , ProHand ... all within Final Cut Pro X . Simply select a ProHand generator and ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- MedSource announced today that it has selected Datatrial,s ... choice.  This latest decision demonstrates MedSource,s commitment to ... by offering a state-of-the-art electronic data capture (EDC) ... the EDC platform of choice in exchange for ... long been a preferred EDC platform by our ...
(Date:6/23/2016)... startling report released today, National Safety Council research shows ... plan to eliminate prescription opioid overdoses. Prescription Nation ... the worst drug crisis in recorded U.S. history, assigned a "Making ... , New Mexico , Tennessee ... states, three – Michigan , Missouri ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... 52" report to their offering. ... creates a favourable commercial environment for MedImmune to enter. The ... that will serve to drive considerable growth for effective anti-influenza ... to cap sales considerably, but development is still in its ...
Breaking Medicine Technology: